Novel therapies for thyroid cancer

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 18, 2014, Pages 2641-2652

  Krajewska, Jolanta ^a   Jarzab, Barbara ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cabozantinib; Differentiated thyroid cancer; Medullary thyroid cancer; Sorafenib; Tyrosine kinase inhibitors; Vandetanib

Indexed keywords

CABOZANTINIB; CALCITONIN; IMATINIB; LENVATINIB; LIOTHYRONINE; MOTESANIB; SORAFENIB; THALIDOMIDE; THYROXINE; VANDETANIB; VASCULOTROPIN INHIBITOR; ANILIDE; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYLPIPERIDIN-4-YL)METHOXY)QUINAZOLIN-4-AMINE; PIPERIDINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; VASCULOTROPIN RECEPTOR;

ABDOMINAL PAIN; ACNE; ALOPECIA; ANOREXIA; APPETITE DISORDER; BLEEDING; CALCITONIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CONGESTIVE HEART FAILURE; DECREASED APPETITE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG SAFETY; DYSGEUSIA; DYSPNEA; ERYTHEMA; EVIDENCE BASED MEDICINE; FATIGUE; HAND FOOT SYNDROME; HEADACHE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERBILIRUBINEMIA; HYPERESTHESIA; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHYSIS; INFECTION; LOSS OF APPETITE; LYMPHOCYTOPENIA; MEDULLARY THYROID CANCER; META ANALYSIS (TOPIC); MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); MUSCULOSKELETAL PAIN; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROTEINURIA; QT PROLONGATION; RASH; REVIEW; SIDE EFFECT; SKIN EXFOLIATION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; THYROID CANCER; THYROID CARCINOMA; THYROID DISEASE; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION; WOUND HEALING IMPAIRMENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); METABOLISM; THYROID NEOPLASMS;

ANILIDES; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DIARRHEA; HUMANS; PHENYLUREA COMPOUNDS; PIPERIDINES; PROTEIN KINASE INHIBITORS; PYRIDINES; QUINAZOLINES; QUINOLINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; THYROID NEOPLASMS;

EID: 84910619732     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.969240     Document Type: Review

References (101)

1. Cramer JD, Fu P, Harth KC, et al. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery 2010;148(6): 1147-52.discussion 1152-3
2. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013: 965212
3. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295(18): 2164-7
4. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1): 9-29
5. Sampson E, Brierley JD, Le LW, et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110(7): 1451-6
6. Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012;22(9): 884-9
7. Mazzaferri EL, Jhiang SM. Long-Term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994.97(5): 418-28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7977430 [Accessed 9 September 2013]
8. Durante C, Haddy N, Baudin E, et al. Long-Term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8): 2892-9
9. Jarza?b B, Sporny S, Lange D, et al. [Diagnosis and treatment of thyroid cancer-polish guidelines]. Endokrynol Pol 61(5): 518-68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21049469 [Accessed 9 September 2013]
10. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154(6): 787-803
11. Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11): 1167-214
12. Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 2012;166(1): 5-11
13. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53, 856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998.83(12): 2638-48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9874472 [Accessed 9 September 2013]
14. Massicotte M-H, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 2014;170(4): 575-82
15. Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107(9): 2134-42
16. Tuttle R, Ball D, Byrd D, Al E. NCCN Clinical practice guidelines in oncologyn (NCCN Guielines); thyroid carcinoma. NCCN Guidel Version 2. Oncologist 2010;15: 212-3. Available from: www.The Oncologist.com
17. Schlumberger M, Bastholt L, Dralle H, et al. 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J 2012;1(1): 5-14
18. Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19(6): 565-612
19. Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165(2): 315-22
20. Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26(29): 4714-19
21. Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28(14): 2323-30
22. Kloos RT, Ringel MD, Knopp M V, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27(10): 1675-84
23. Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359(1): 31-42
24. Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27(23): 3794-801
25. Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26(29): 4708-13
26. Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10): 962-72
27. Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 2014;99(5): 1687-93
28. Ravaud A, de la Fouchardieggggre C, Asselineau J, et al. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 2010;15(2): 212-13.author reply 214
29. Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16(21): 5260-8
30. Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9): 897-905
31. Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2): 134-41
32. Elisei R, Schlumberger MJ, Muddddller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31(29): 3639-46
33. Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940): 319-28
34. Schlumberger M, Tahara M, Wirth L, et al. A phase 3, multicenter, double blind, placebo-controlled trial of lenvatinib (E7080) in patients 131Irefractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;32(Suppl): LBA6008
35. Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999.17(1): 380-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10458257 [Accessed 17 July 2014]
36. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014;14(3): 173-86
37. Eng C, Mulligan LM, Smith DP, et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 1995;12(3): 209-12
38. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93(3): 682-7
39. Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009;100(11): 1777-83
40. Dvorakova S, Vaclavikova E, Sykorova V, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 2008;284(1-2): 21-7
41. Giunti S, Antonelli A, Amorosi A, Santarpia L. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol 2013;2013: 803171
42. Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003.95(8): 625-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12697856 [Accessed 13 July 2014]
43. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003.63(7): 1454-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12670889 [Accessed 13 July 2014]
44. Salvatore G, De Falco V, Salerno P, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12(5): 1623-9
45. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12(2): 245-62
46. Antonelli A, Fallahi P, Ferrari SM, et al. New targeted therapies for thyroid cancer. Curr Genomics 2011;12(8): 626-31
47. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148(3): 936-41
48. Espinosa A V, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96(1): 16-20
49. Giusti F, Falchetti A, Franceschelli F, et al. Thyroid cancer: current molecular perspectives. J Oncol 2010;2010: 351679
50. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3): 184-99
51. Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997;82(11): 3741-7
52. De la Torre NG, Buley I, Wass JA, Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 2006;13(3): 931-44
53. Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001;86(2): 656-8
54. Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155(6): 1967-76
55. Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23(6): 713-22
56. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002.62(24): 7284-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12499271 [Accessed 9 July 2014]
57. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002.62(16): 4645-55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12183421 [Accessed 9 July 2014]
58. Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28(5): 767-72
59. Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95(6): 2664-71
60. Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 2013;19(15): 4239-48
61. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12): 2298-308
62. Bentzien F, Zuzow M, Heald N, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 2013;23(12): 1569-77
63. Zhang Y, Guessous F, Kofman A, et al.-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010.13(2): 112-21. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3268517&tool=pmcentrez&rendertype=abstract [Accessed 12 July 2014]
64. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19): 2660-6
65. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19): 7099-109
66. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98(5): 326-34
67. Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161(6): 923-31
68. Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19(2): 209-16
69. Krajewska J, Olczyk T, Roskosz J, et al. Treatment with sorafenib in advanced thyroid cancer-A case report. Endokrynol Pol 61.5): 492-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21049464 [Accessed 13 July 2014]
70. Shen Y, Ruan M, Luo Q, et al. Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. Thyroid 2012;22(8): 856-60
71. Waguespack SG, Sherman SI, Williams MD, et al. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 2009;19(4): 407-12
72. Iyer P, Mayer JL, Ewig JM. Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. Thyroid 2014;24(1): 169-74
73. Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17): 5459-65
74. Glen H, Mason S, Patel H, et al. E7080, a multi-Targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011;11: 309
75. Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-Tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340(1): 97-103
76. Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 2014;99(6): 2086-94
77. Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-Analysis. PLoS One 2012;7(2): e30353
78. Vandetanib: too dangerous in medullary thyroid cancer. Prescrire Int 2012.21(131): 233. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23185843 [Accessed 14 July 2014]
79. Chen L, Shen Y, Luo Q, et al. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 2011;21(2): 119-24
80. Shen C-T, Qiu Z-L, Luo Q-Y. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-Analysis. Endocr Relat Cancer 2014;21(2): 253-61
81. Senapati J, Devasia AJ, Ganapule A, et al. Sorafenib Induced hand foot skin rash in FLT3 ITD mutated acute myeloid leukemia-A case report and review of literature. Mediterr J Hematol Infect Dis 2014;6(1): e2014016
82. Sherman S, Jarzab B, Cabanillas M, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011;29(Suppl): 5503
83. Schlumberger M, Jarzab B, Cabanillas M, et al. A phase II trial of multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). J Clin Oncol 2012;30(Suppl): 5591
84. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96(12): 1788-95
85. Krajewska J, Jarzab B. Lenvatinib for the treatment of follicular and papillary thyroid cancer. Expert Opin Orphan Drugs 2014; doi: 10.1517/21678707.2014.962514
86. Zhang Z-F, Wang T, Liu L-H, Guo H-Q. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-Analysis. PLoS One 2014;9(3): e90135
87. Qi W-X, Sun Y-J, Tang L-N, et al. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-Analysis. Crit Rev Oncol Hematol 2014;89(3): 394-403
88. Qi W, Shen Z, Tang L, Yao Y. Congestive heart failure risk in cancer patients treated with VEGFR-TKIs: a systematic review and meta-Analysis of 36 clinical trials. Br J Clin Pharmacol 2014;78(4): 748-62
89. Qi W-X, Min D-L, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-Analysis. Int J Cancer 2013;132(12): 2967-74
90. Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46(2): 439-48
91. Keizer RJ, Gupta A, Mac Gillavry MR, et al. A model of hypertension and proteinuria in cancer patients treated with the anti-Angiogenic drug E7080. J Pharmacokinet Pharmacodyn 2010;37(4): 347-63
92. Illouz F, Laboureau-Soares S, Dubois S, et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 2009;160(3): 331-6
93. Scheffel RS, Dora JM, Siqueira DR, et al. Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis. Eur J Endocrinol 2013;168(6): K51-4
94. Toubert M-E, Vercellino L, Faugeron I, et al. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid 2011;21(4): 451-4
95. Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-Term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 2013;31(32): 4046-53
96. Feldt S, Schuddddssel K, Quinzler R, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer 2012;48(7): 974-81
97. Makita N, Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 2013;23(2): 151-9
98. Illouz F, Braun D, Briet C, et al. Thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 2014;171(3): 91-9; doi: 10.1530/EJE-14-0198. [Epub 2014 May 15]
99. Abdulrahman RM, Verloop H, Hoftijzer H, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 2010;95(8): 3758-62
100. Braun D, Kim TD, le Coutre P, et al. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab 2012;97(1): E100-5
101. Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 2013;7(2): 162-7